YHR2501

YHR2501 is an investigational pharmaceutical agent developed by Yuhan Corporation. It is being evaluated in a phase 1 bioequivalence clinical trial as the comparator to YHP2406. The trial involves administering a single oral dose of each drug in a crossover design to healthy volunteers, with the primary objective being to compare the pharmacokinetic profiles and determine bioequivalence. The indication for YHR2501 is not publicly disclosed; the study population consists of healthy subjects, and the drug's mechanism of action and specific therapeutic area remain undisclosed. The study sponsor and developer is Yuhan Corporation. The investigation is currently not yet recruiting and is conducted in the Republic of Korea[1][3][5][7][9].